Progesterone Receptor-negative Breast Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028547 (Progesterone Receptor-negative Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00733408Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerTreatment